Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
22 November 1989Website:
http://www.biolifesolutions.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 27 Sep 2024 20:02:32 GMTDividend
Analysts recommendations
Institutional Ownership
BLFS Latest News
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Rod de Greef – Chairman and Chief Executive Officer Garrie Richardson – Chief Revenue Officer Conference Call Participants Jacob Johnson – Stephens Anna Snopkowski – KeyBanc Matt Stanton – Jefferies Steven Mah – TD Cowen Thomas Flaten – Lake Street Capital Markets Operator Good afternoon, and welcome to the BioLife Solutions Q2 2024 Shareholder and Analyst Conference Call. [Operator Instructions] Please note, this event is being recorded.
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.23 per share a year ago.
Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation. BOTHELL, Wash.
BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
BioLife Solutions, Inc. is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. The company offers bioproduction tools and services for the cell and gene therapy industry, with recurring revenue streams making up about 65% of its revenue. The cell and gene therapy market is expected to continue growing, but BioLife's recent financial performance and management changes have caused concern.
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Rod de Greef - Chairman and CEO Conference Call Participants Jacob Johnson - Stephen Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Steven Mah - TD Cowen Thomas Flaten - Lake Street Michael Okunewitch - Maxim Group Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst Conference Call.
BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.
BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter.
What type of business is BioLife Solutions?
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
What sector is BioLife Solutions in?
BioLife Solutions is in the Healthcare sector
What industry is BioLife Solutions in?
BioLife Solutions is in the Medical Instruments & Supplies industry
What country is BioLife Solutions from?
BioLife Solutions is headquartered in United States
When did BioLife Solutions go public?
BioLife Solutions initial public offering (IPO) was on 22 November 1989
What is BioLife Solutions website?
https://www.biolifesolutions.com
Is BioLife Solutions in the S&P 500?
No, BioLife Solutions is not included in the S&P 500 index
Is BioLife Solutions in the NASDAQ 100?
No, BioLife Solutions is not included in the NASDAQ 100 index
Is BioLife Solutions in the Dow Jones?
No, BioLife Solutions is not included in the Dow Jones index
When was BioLife Solutions the previous earnings report?
No data
When does BioLife Solutions earnings report?
The next expected earnings date for BioLife Solutions is 08 November 2024